Triple-Threat attack on aggressive blood cancers shows promise
NCT ID NCT05010122
First seen Nov 01, 2025 · Last updated Apr 21, 2026 · Updated 26 times
Summary
This study is testing a combination of three drugs—ASTX727, venetoclax, and gilteritinib—to treat adults with specific types of aggressive blood cancers (AML or MDS) that have an FLT3 gene mutation. The goal is to find the safest dose and see how well the combination works to control the disease in patients who are newly diagnosed or whose cancer has returned or resisted treatment. Researchers hope this approach will be more effective than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.